Targeted Protein Degradation of Tau & Alpha-Synuclein For Preventing Neurodegeneration in Alzheimer’s & Parkinson’s Disease
Time: 1:30 pm
day: Clinical & Commercial Track PM
Details:
- Harnessing protein degradation technology using dual function target binders and E3-ligase ligands to degrade pathological protein aggregates via the ubiquitinproteasome system
- Investigating selectivity and specificity of mechanism of action in cells and in vivo
- Using proprietary diagnostic radiotracers to select patients and provide both target engagement and efficacy readouts
